KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Pacific Biosciences Of California (PACB) over the last 12 years, with Q2 2023 value amounting to $162000.0.

  • Pacific Biosciences Of California's Amortization of Deferred Charges rose 125.0% to $162000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $645000.0, marking a year-over-year increase of 205.7%. This contributed to the annual value of $640000.0 for FY2022, which is 1873.84% up from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Amortization of Deferred Charges of $162000.0 as of Q2 2023, which was up 125.0% from $162000.0 recorded in Q1 2023.
  • In the past 5 years, Pacific Biosciences Of California's Amortization of Deferred Charges ranged from a high of $735000.0 in Q3 2020 and a low of -$2.0 million during Q4 2020
  • Its 5-year average for Amortization of Deferred Charges is $158000.0, with a median of $160500.0 in 2022.
  • Examining YoY changes over the last 5 years, Pacific Biosciences Of California's Amortization of Deferred Charges showed a top increase of 17552.74% in 2019 and a maximum decrease of 36981.82% in 2019.
  • Pacific Biosciences Of California's Amortization of Deferred Charges (Quarter) stood at -$742000.0 in 2019, then tumbled by 169.27% to -$2.0 million in 2020, then skyrocketed by 107.91% to $158000.0 in 2021, then increased by 1.27% to $160000.0 in 2022, then rose by 1.25% to $162000.0 in 2023.
  • Its last three reported values are $162000.0 in Q2 2023, $162000.0 for Q1 2023, and $160000.0 during Q4 2022.